Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: LGND stock price vs HEI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HEI's multiple
Needs HEI P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · HEI FY 2025 (ended Oct 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 94% equity / 6% debt · EV / Revenue 19.90x · EV / EBITDA 33.28x
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 89% equity / 11% debt
HEI carries the larger enterprise value at $20.12B against $5.33B; HEI trades on the lower EV / Revenue multiple (4.49x vs 19.90x); HEI on the lower EV / EBITDA (19.52x vs 33.28x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
HEICO CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.37x
0.50x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
—
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
—
Total debt
Interest-bearing obligations outstanding
$374.08M
$2.17B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
TransDigm Group INC
LGND vs TDG
Spirit AeroSystems Holdings, Inc.
LGND vs SPR
CURTISS WRIGHT CORP
LGND vs CW
RTX Corp
LGND vs RTX
GENERAL ELECTRIC CO
LGND vs GE
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
